Evidence map›Paper›PMID 40909036›Full record

ArticleCureus2025

A CDC WONDER Study on Disparities in Place of Death Among Patients With Systemic Lupus Erythematosus in the United States between 1999 and 2020.

Aruna Anantharaj, Dr Rohit Rao Yelagapuri, Parth Vikram Singh, Aayza Nadeem, Shreya Deoghare

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aruna AnantharajInternal Medicine, Wuhan University School of Medicine, Hubei, CHN.
Dr Rohit Rao YelagapuriIntensive Care Unit, Ramdev Rao Hospital, Hyderabad, IND.
Parth Vikram SinghInternal Medicine, Indira Gandhi Government Medical College, Nagpur, IND.
Aayza NadeemInternal Medicine, Jinnah Sindh Medical University, Karachi, PAK.
Shreya DeoghareDermatology, N.K.P. Salve Institute of Medical Sciences and Research Centre, Nagpur, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSystemic lupus erythematosus (SLE) is an autoimmune disease, more prevalent among African-American women, often associated with severe manifestations such as lupus nephritis and neuropsychiatric lupus. Both conditions contribute significantly to morbidity and mortality, though lupus nephritis is more commonly linked to direct disease-related deaths. Mortality can also result from other severe disease manifestations or treatment-related complications. Assessing disparities in place of death among lupus patients is essential for improving care quality through targeted physician and patient education.

aimsThe aim of this study is to evaluate disparities in the place of death (hospital, nursing home, hospice, and home) among lupus patients in the United States of America (USA), based on demographic characteristics like age, gender, race, and geographic regions. METHODOLOGY: A retrospective study was conducted in September 2023 using Centers for Disease Control and Prevention - Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) data, focused on deaths attributed to lupus erythematosus (International Classification of Diseases, Tenth Revision (ICD-10) Code: L93, including L93.0, L93.1, and L93.2). It analyzed disparities in death location (home/hospice, medical facility/nursing home, others that include unknown locations or unspecified categories where the place of death could not be conclusively determined) across four variables employing statistical tools STATA15 (StataCorp LLC, College Station, TX) and R3.6.3 (The R Core Team, R Foundation for Statistical Computing, Vienna, Austria).

resultsA total of 3,937 deaths from 1999 to 2020 were included in the analysis from the CDC WONDER database, which showed 1,269 deaths were in home/hospice, 2,517 in medical/nursing facilities, and 151 at other unknown/unspecified locations. Higher odds of home/hospice deaths were noted in ages 55-64 years (1.606) and 65-74 years (1.576), males (1.306 times more than females), patients who were American Indian/Alaska Native (3.447), and those in Census region 3: South (1.459).

conclusionsLupus patients above 50 years, males, and those of American Indian/Alaskan race, and from the Census region 3 (South) have an increased likelihood of dying in home/hospice care. Future predictions till 2025 using the AutoRegressive Integrated Moving Average (ARIMA) model indicate an increasing trend of cumulative home/hospice mortality.

Indexed as

autoimmunehospice caremortality trendsneuropsychiatric systemic lupus erythematosus (npsle)systemic lupus erythematosus

Identifiers

PMID40909036
PMCPMC12405955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.